Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11880012 | 0.81 | CA2 (0.43) | CA2ALOX5ATMNISCHHTT | |
| SCHEMBL4553391 | 0.80 | HTT (0.47) | CA2HTTALDH1A1HPGDMTNR1A | |
| SCHEMBL11391442 | 0.76 | ALOX5 (0.64) | CA2ALOX5HTTHTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL10926011 | 0.75 | ALOX5 (0.62) | CA2ALOX5HTTHTR1AADRA2A | |
| SCHEMBL407103 | 0.74 | ALDH1A1 (0.51) | CA2HSD17B10HTTALDH1A1HPGD | |
| SCHEMBL21638742 | 0.74 | CES1 (0.46) | CA2HTTALDH1A1HPGD | |
| SCHEMBL9281031 | 0.73 | ATM (0.50) | CA2ALOX5ATMHSD17B10NISCH | |
| SCHEMBL442707 | 0.73 | ATM (0.50) | CA2ALOX5ATMNISCHSIRT1 | |
| SCHEMBL11109767 | 0.72 | HSD17B10 (0.46) | ATMHSD17B10HTTALDH1A1HPGD | |
| SCHEMBL17761374 | 0.72 | HRH3 (0.43) | CA2ALOX5NISCHHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937096-B2 | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8853263-B2 | Co-therapy for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8716231-B2 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-06 | — | — | US | disclosed |
| US-8691867-B2 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-08 | — | — | US | disclosed |
| US-8497298-B2 | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-30 | — | — | US | disclosed |
| US-8492431-B2 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-07-23 | — | — | US | disclosed |
| US-20120065257-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | SMITH-SWINTOSKY VIRGINIA L (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065257-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | SMITH-SWINTOSKY VIRGINIA L (US) | 2012-03-15 | — | — | US | disclosed |
| US-8084490-B2 | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-27 | — | — | US | disclosed |
| US-8084490-B2 | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-27 | — | — | US | disclosed |
| US-20070293440-A1 | O-fused heterocycle sulfonylurea compounds with another anticonvulsant or antiepileptic agent such as carbamazepine | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-20 | — | — | US | disclosed |
| US-20070191474-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155821-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR LOWERING LIPIDS AND LOWERING BLOOD GLUCOSE LEVELS | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155827-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155826-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155822-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155825-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155823-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | US | disclosed |
| US-3969368-A | 2-Substituted benzodioxoles | ISTITUTO LUSO FARMACO D'ITALIA S.R.L. (IT) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155822-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | SULT2A1, OPRL1, NPSR1 | CA2 599/4885ALOX5 522/4885ATM 4506/4885 |
| US-20070155823-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES AS NEUROPROTECTIVE AGENTS | SMN1; SMN2, BDNF, SIRT1 | CA2 3235/4885ALOX5 1025/4885ATM 2222/4885 |
| US-20070155824-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR DISEASE MODIFICATION / EPILEPTOGENESIS | STS, GABRB2, SULT2A1 | CA2 826/4885ALOX5 559/4885ATM 4431/4885 |
| US-20070155827-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | SDHA, SQOR, SDHB | CA2 3045/4885ALOX5 1848/4885ATM 3484/4885 |
| US-20070191474-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | CNR2, FAAH2, CCKBR | CA2 545/4885ALOX5 989/4885ATM 3440/4885 |
| US-20070155825-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF SUBSTANCE ABUSE AND ADDICTION | SULT2A1, SULT1A1, STS | CA2 4329/4885ALOX5 1599/4885ATM 2654/4885 |
| US-20070293440-A1 | O-fused heterocycle sulfonylurea compounds with another anticonvulsant or antiepileptic agent such as carbamazepine | GABBR1, GABRB2, GABRE | CA2 451/4885ALOX5 1867/4885ATM 4717/4885 |
| US-20120065257-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | CNR2, FAAH2, CCKBR | CA2 545/4885ALOX5 989/4885ATM 3440/4885 |
| US-20070155826-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | GABBR1, GABBR2, SQOR | CA2 2789/4885ALOX5 2649/4885ATM 4546/4885 |
| US-20070155821-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR LOWERING LIPIDS AND LOWERING BLOOD GLUCOSE LEVELS | GPR119, LIPC, GLP1R | CA2 2709/4885ALOX5 664/4885ATM 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.